This article originally appeared at

Authors Silvia Kochen  1 Manuela Villanueva  1 Liliana Bayarres  1 Anilu Daza-Restrepo  1 Silvia Gonzalez Martinez  1 Silvia Oddo  2



Cannabidiol oil (CBD) has been approved as an anti-seizure medication for the treatment of uncommon types of epilepsy, occurring in children: Dravet syndrome, Lennox-Gastaut syndrome, and Tuberous Sclerosis Complex. There are few publications in relation to use the CBD in adult patients with focal drug-resistant epilepsy. The objective of this study was to evaluate the efficacy, tolerability, safety, and quality of life, of adjuvant treatment with CBD, in adult patients with drug-resistant focal epilepsy for at least 6 months.

An open, observational, prospective cohort study was conducted using a before-after design (time series) in adult patients undergoing outpatient follow-up in a public hospital in Buenos Aires, Argentina.

From a total of 44 patients, 5% of patients were seizure-free, 32% of patients reduced more than 80% of their seizures and 87% of patients reduced 50% of their monthly seizures. Eleven percent presented a decrease of less than 50% in seizure frequency.

The average final dose was 335 mg/d orally administered. Thirty-four percent of patients reported mild adverse events and no patient reported severe adverse effects. At the end of the study, we found in most patients a significant improvement in the quality of life, in all the items evaluated.

Adjuvant treatment with CBD in adult patients with drug-resistant focal epilepsy was effective, safe, well tolerated, and associated with a significant improvement in their quality of life.


  1. Li H-L. The origin and use of cannabis in eastern Asia linguistic-cultural szaimplications. Economic Botany 1974;28(3):293–301. McCoy B, Wang L, Zak M, Al-Mehmadi S, Kabir N, Alhadid K, et al. A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome. Ann Clin Transl Neurol 2018;5(9):1077–88.View in Article
    • Mechoulam R.
    • Carlini E.A.
    Toward drugs derived from cannabis.Naturwissenschaften. 1978; 65: 174-179View in Article
    • Carlini E.A.
    • Leite J.R.
    • Tannhauser M.
    • Berardi A.C.
    Cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents.J Pharm Pharmacol. 1973; 25: 664-665View in Article
  2. Izquierdo I, Nasello AG. Effects of cannabidiol and of diphenylhydantoin on the hippocampus and on learning. Psychopharmacologia [Internet] 1973;31(2):167–75. Available from: in Article
    • Matsuda L.A.
    • Lolait S.J.
    • Brownstein M.J.
    • Young A.C.
    • Bonner T.I.
    Structure of a cannabinoid receptor and functional expression of the cloned cDNA.Nature. 1990; 346: 561-564 in Article
    • Devane W.A.
    • Hanus L.
    • Breuer A.
    • Pertwee R.G.
    • Stevenson L.A.
    • Griffin G.
    • et al.
    Isolation and structure of a brain constituent that binds to the cannabinoid receptor.Science. 1992; 258: 1946-1949 in Article
    • Fiore M.
    • Pereira P.
    The Politics of Evaluating Cannabis Regulation in Uruguay.Novos Estudos – CEBRAP. 2021; 40: 103-124View in Article
  3. World Health Organization 2020. UN Commission on Narcotic Drugs reclassifies cannabis to recognize its therapeutic uses. in Article
  4. Kochen S, Cannabis medicinal, Editorial. Salud Colectiva, Universidad Nacional de Lanús, 2022. ISSN 1669-2381 | EISSN 1851-8265 | doi: 10.18294/sc..3991.View in Article
    • Kwan P.
    • Arzimanoglou A.
    • Berg A.T.
    • Brodie M.J.
    • Hauser W.A.
    • Mathern G.
    • et al.
    Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies.Epilepsia. 2010; 51: 1069-1077View in Article
    • Chen Z.
    • Brodie M.J.
    • Liew D.
    • Kwan P.
    Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs a 30-year longitudinal cohort study.JAMA Neurol. 2018; 75: 279-286View in Article
    • Franco V.
    • Perucca E.
    Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy.Drugs [Internet]. 2019; 79 (Available from: 1435-1454View in Article
  5. EMA 2019: in Article
  6. FDA 2018: in Article
  7. FDA 2022: in Article
  8. Gaston T, Szaflarski JP. Cannabis for the Treatment of Epilepsy: an Update. Curr Neurol Neurosci Rep 2018;18(11).View in Article
    • Devinsky O.
    • Marsh E.
    • Friedman D.
    • Thiele E.
    • Laux L.
    • Sullivan J.
    • et al.
    Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.Lancet Neurol. 2016; 15: 270-278View in Article
    • Devinsky O.
    • Cross J.H.
    • Laux L.
    • Marsh E.
    • Miller I.
    • Nabbout R.
    • et al.
    Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.N Engl J Med. 2017; 376 (Available from): 2011-2020 in Article
    • Miller I.
    • Scheffer I.E.
    • Gunning B.
    • Sanchez-Carpintero R.
    • Gil-Nagel A.
    • Perry M.S.
    • et al.
    GWPCARE2 Study Group. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial.JAMA Neurol. 2020; 77: 613-621 in Article
    • Devinsky O.
    • Patel A.D.
    • Cross J.H.
    • Villanueva V.
    • Wirrell E.C.
    • Privitera M.
    • et al.
    GWPCARE3 Study Group. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome.N Engl J Med. 2018; 378: 1888-1897 in Article
  9. Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. GWPCARE4 Study Group, 2018 17. Cannabidiol in patients with seizures associated with Lennox-.View in Article
    • Thiele E.A.
    • Bebin E.M.
    • Filloux F.
    • Kwan P.
    • Loftus R.
    • Sahebkar F.
    • et al.
    Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial.Epilepsia. 2021; 63: 426-439View in Article
    • Lattanzi S.
    • Trinka E.
    • Striano P.
    • Rocchi C.
    • Salvemini S.
    • Silvestrini M.
    • et al.
    Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.CNS Drugs [Internet]. 2021; 35 (Available from: 265-281View in Article
    • Carlson M.D.A.
    • Morrison R.S.
    Study Design, Precision, and Validity in Observational Studies.J Palliative Med [Internet]. 2009; 12 (Available from): 77-82 in Article
    • Bosdriesz J.R.
    • Stel V.S.
    • van Diepen M.
    • Meuleman Y.
    • Dekker F.W.
    • Zoccali C.
    • et al.
    Evidence-based medicine—When observational studies are better than randomized controlled trials.Nephrology. 2020; 25: 737-743View in Article
    • Metelli S.
    • Chaimani A.
    Challenges in meta-analyses with observational studies.Evidence Based Mental Health. 2020; 23: 83-87View in Article
    • Rosenberg E.C.
    • Louik J.
    • Conway E.
    • Devinsky O.
    • Friedman D.
    Quality of life in childhood epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol.Epilepsia. 2017; 58: 96-100View in Article
    • Devinsky O.
    • Verducci C.
    • Thiele E.A.
    • Laux L.C.
    • Patel A.D.
    • Filloux F.
    • et al.
    Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.Epilepsy Behav. 2018; 86: 131-137View in Article
    • Szaflarski J.P.
    • Bebin E.M.
    • Comi A.M.
    • Patel A.D.
    • Joshi C.
    • Checketts D.
    • et al.
    Long-term safety and treatment effects of cannabidiol in children and adults with treatment resistant epilepsies: expanded access program results.Epilepsia. 2018; 59: 1540-1548View in Article
    • Kochen S.
    • Manin A.
    • Montiel R.
    Artisanal Cannabis in Young and Adults Patients with Treatment Resistant Epilepsy: Prospective, Observational, Open-Label Study in Argentina.J Neurol Neurol Disorders. 2018; 4: 202 in Article
    • Devinsky O.
    • Cilio M.R.
    • Cross H.
    • Fernandez-Ruiz J.
    • French J.
    • Hill C.
    • et al.
    Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.Epilepsia. 2014; 55: 791-802View in Article
    • Szaflarski J.P.
    • Devinsky O.
    • Lopez M.
    • Park Y.D.
    • Zentil P.P.
    • Patel A.D.
    • et al.
    Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: Four-year results from the expanded access program.Epilepsia [Internet]. 2022; in Article
    • Hausman-Kedem M.
    • Menascu S.
    • Kramer U.
    Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents. An observational, longitudinal study.Brain Dev. 2018; 40: 544-555View in Article
    • Pesántez Ríos G.
    • Armijos Acurio L.
    • Jimbo Sotomayor R.
    • Cueva V.
    • Pesántez Ríos X.
    • Navarrete Zambrano H.
    • et al.
    A Pilot Study on the Use of Low Doses of CBD to Control Seizures in Rare and Severe Forms of Drug-Resistant Epilepsy.Life. 2022; 12: 2065 in Article
    • Caraballo R.
    • Reyes G.
    • Demirdjian G.
    • Huaman M.
    • Gutierrez R.
    Long-term use of cannabidiol-enriched medical cannabis in a prospective cohort of children with drug-resistant developmental and epileptic encephalopathy.Seizure. 2022; 95: 56-63View in Article
    • Cunha J.M.
    • Carlini E.A.
    • Pereira A.E.
    • Ramos O.L.
    • Pimentel C.
    • Gagliardi R.
    • et al.
    Chronic administration of cannabidiol to healthy volunteers and epileptic patients.Pharmacology. 1980; 21: 175-185View in Article
    • Nenert R.
    • Allendorfer J.B.
    • Bebin M.
    • Gaston T.E.
    • Grayson L.E.
    • Houston J.T.
    • et al.
    Cannabidiol normalizes resting-state functional connectivity in treatment-resistant epilepsy.Epilepsy Behav. 2020; 112107297 020View in Article
    • Billakota S.
    • Devinsky O.
    • Marsh E.
    Cannabinoid therapy in epilepsy.Curr Opin Neurol. 2019; 32: 220-226View in Article
    • Perucca E.
    Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?.J Epilepsy Res [Internet]. 2017; 7 (Available from): 61-76 in Article
    • Huestis M.A.
    • Solimini R.
    • Pichini S.
    • Pacifici R.
    • Carlier J.
    • Busardò F.P.
    Cannabidiol Adverse Effects and Toxicity.Curr Neuropharmacol [Internet]. 2019; 17 (Available from: 974-989View in Article
    • Von Wrede R.
    • Helmstaedter C.
    • Surges R.
    Cannabidiol in the Treatment of Epilepsy.Clin Drug Invest. 2021; 41: 211-220View in Article

Article info

Publication history

Published online: May 15, 2023

Accepted: April 1, 2023

Received in revised form: March 30, 2023

Received: February 27, 2023